Evidence map›Paper›PMID 37060356›Full record

ArticleJournal of pediatric endocrinology & metabolism : JPEM2023

Prevalence of nonalcoholic fatty liver disease increased with type 2 diabetes mellitus in overweight/obese youth with polycystic ovary syndrome.

Namrata Patel-Sanchez, Emily Perito, Patrika Tsai, Marissa Raymond-Flesch, Maya Lodish, Monika Sarkar

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pediatric endocrinology & metabolism : JPEM, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Metabolic Implications of PCOS.Current pediatrics reports · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Namrata Patel-SanchezDepartment of Gastroenterology, University of California, San Francisco, Benioff Children's Hospital- Oakland, Oakland, CA, USA.ORCID https://orcid.org/0000-0002-0124-4643
Emily PeritoDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of California, San Francisco, Benioff Children's Hospital- San Francisco, San Francisco, CA, USA.
Patrika TsaiDepartment of Pediatrics, Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of California, San Francisco, Benioff Children's Hospital- San Francisco, San Francisco, CA, USA.
Marissa Raymond-FleschDepartment of Pediatrics, Division of Adolescent Medicine, University of California, San Francisco, CA, USA.
Maya LodishDepartment of Pediatrics, Division of Pediatric Endocrinology, University of California, San Francisco, CA, USA.
Monika SarkarDepartment of Gastroenterology, University of California, San Francisco, CA, USA.
University of California, San Francisco · US

Funding

TRAINING PROGRAM IN PEDIATRIC GASTROENTEROLOGY/NUTRITIONT32DK007762 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI James Bayrer · 1998 to 2026
$7.3M
NIDDK NIH HHS T32 DK007762
6 · The paper itself

Abstract

objectivesPolycystic ovary syndrome (PCOS) increases non-alcoholic fatty liver disease (NAFLD) risk and severity in adults, but data in adolescents with diverse backgrounds are limited. We evaluated NAFLD prevalence and characterized NAFLD risk factors in overweight/obese adolescents by PCOS status.

methodsRetrospective study of overweight (n=52)/obese (n=271) female adolescents (12-18 years old), evaluated clinically 2012-2020, was conducted comparing PCOS patients to age-matched non-PCOS controls. NAFLD was defined as ALT≥44U/L x2 and/or ≥80U/L x1, hepatic steatosis on imaging, or NAFLD on biopsy, in absence of other liver disease. Metabolic comorbidities were captured. Log-binomial regression models estimated prevalence risk ratios (PR).

resultsNAFLD prevalence was 19.1 % in adolescents with PCOS (n=161), similar to those without (n=162) (16.8 %, p=0.6). Adolescents with PCOS were more likely to have insulin resistance, hypercholesterolemia, and higher triglycerides (p<0.05). Those with PCOS and concomitant type 2 diabetes (T2DM) did have increased NAFLD risk (PR 2.5, p=0.04), but those with PCOS without T2DM did not (PR 0.9, p=0.8). Adolescents with PCOS and NAFLD, compared to those with PCOS without NAFLD, had a higher prevalence of metabolic comorbidities including hypercholesterolemia (77 vs. 48 %), T2DM (29 vs. 8 %), and hypertriglyceridemia (65 vs. 37 %) (p<0.01).

conclusionsAlmost 1 in 5 overweight/obese female adolescents had NAFLD, but PCOS did not increase NAFLD risk in this diverse cohort. Among young women with PCOS, concomitant T2DM did increase the risk for NAFLD. Closer monitoring of obesity comorbidities in adolescents with PCOS is essential for optimizing health and merits updating current guidelines.

Indexed as

Diabetes Mellitus, Type 2HypercholesterolemiaInsulin ResistanceNon-alcoholic Fatty Liver DiseasePolycystic Ovary SyndromeAdolescentAdultChildFemaleHumansObesityOverweightPrevalenceRetrospective StudiesRisk FactorsNAFLDnon-alcoholic fatty liver diseasePCOSpediatric NAFLDpolycystic ovary syndrometype 2 diabetes

Identifiers

PMID37060356
PMCPMC10214017
OpenAlexW4365810707

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.